Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies

Published:2022-08 Issue: Volume:22 Page:101459
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Atilla Pinar Ataca^ORCID,Atilla Erden^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference137 articles.

1. Tragedy, perseverance, and chance - the story of CAR- T therapy;Rosenbaum;N. Engl. J. Med.,2017

2. Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity;Caruso;Cancer Res.,2015

3. Excessively high-affinity single- chain fragment variable region in a chimeric antigen receptor can counteract T-cell proliferation;Watanabe;Blood,2014

4. Designing chimeric antigen receptors to effectively and safely target tumors;Jensen;Curr. Opin. Immunol.,2015

5. The optimal antigen response of chimeric antigen receptors harboring the CD3ζ transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex;Bridgeman;J. Immunol.,2010

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration;Cancer Medicine;2024-09

2. Effects of Consolidation Therapy With Autologous Hematopoietic Stem Cell Transplantation After BCMA-CAR T-Cell Therapy on the Survival of Patients With Relapsed or Refractory Multiple Myeloma;Transplantation and Cellular Therapy;2024-09

3. Obstacles to global implementation of CAR T cell therapy in myeloma and lymphoma;Frontiers in Oncology;2024-07-19

4. Unraveling resistance mechanisms in anti-CD19 chimeric antigen receptor-T therapy for B-ALL: a novel in vitro model and insights into target antigen dynamics;Journal of Translational Medicine;2024-05-21

5. Oncotherapy resistance explained by Darwinian and Lamarckian models;Journal of Clinical Investigation;2024-04-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3